CMPX, Maze Therapeutics
Is Compass Therapeutics (NASDAQ:CMPX) Gaining Momentum with Institutional Backing
Highlights,Compass Therapeutics sees increased institutional engagement, with major firms expanding their holdings.,Research firms adjust ratings, reflecting varied perspectives on the company’s market trajectory.,The company advances lead therapeutic can...
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary ...
Compass Therapeutics' lead candidate, tovecimig, shows mixed data in various trials, with a significant upcoming phase 3 ...
Compass Therapeutics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the sector are Castle Biosciences CSTL, BioMarin Pharmaceutical BMRN and Alnylam Pharmaceuticals ALNY.
In 2024, we established a strong foundation for what we expect will be a transformational year ahead for Compass,” said Thomas Schuetz, MD, ...
BOSTON - Compass Therapeutics, Inc. (NASDAQ: CMPX) shares gained 2.7% after the clinical-stage oncology company reported progress across its pipeline and provided a business updat ...
Shares of Compass Therapeutics (NASDAQ:CMPX) were up 8% in afternoon trading Monday after Guggenheim initiated coverage of ...
As of December 31, 2024, cash and marketable securities were $127 million as compared to $152 million as of December 31, 2023, providing the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback